High-dose melphalan followed by auto-SCT has favorable safety and efficacy in selected patients with light chain deposition disease and light and heavy chain deposition disease

Bone Marrow Transplantation

Volumn 47, Issue 3, 2012, Pages 453-455

  Telio, D ^a   Shepherd, J ^a,b   Forrest, D ^a,b   Zypchen, L ^a   Barnett, M ^a,b   Nevill, T ^a,b   Song, K W ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CREATININE; DEXAMETHASONE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE KIDNEY FAILURE; ADULT; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HEAVY CHAIN DEPOSITION DISEASE; HEAVY CHAIN LIGHT DEPOSITION DISEASE; HUMAN; IMMUNOGLOBULIN DEPOSITION; KIDNEY BIOPSY; LETTER; LIGHT CHAIN DEPOSITION DISEASE; MALE; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PATIENT SAFETY; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROTEINURIA; TREATMENT RESPONSE;

EID: 85027921644     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.87     Document Type: Letter

References (9)

1. Ronco P, Plaisier E, Mougenot B, Aucouturier P. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol 2006; 1: 1342-1350.
2. Pozzi C, D'Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 2003; 42: 1154-1163. (Pubitemid 37486758)
3. Heilman RL, Velosa JA, Holley KE, Offord KP, Kyle RA. Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis 1992; 20: 34-41.
4. Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 2005; 79: 319-328. (Pubitemid 41098849)
5. Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR et al. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 2008; 23: 2052-2057. (Pubitemid 351768166)
6. Weichman K, Dember LM, Prokaeva T, Wright DG, Quillen K, Rosenzweig Met al. Clinical and molecular characteristics of patients with non-amyloid light chain deposition disorders, and outcome following treatment with high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2006; 38: 339-343.
7. Hassoun H, Flombaum C, D'Agati VD, Rafferty BT, Cohen A, Klimek VM et al. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant 2008; 42: 405-412.
8. Royer B, Arnulf B, Martinez F, Roy L, Flageul B, Etienne I et al. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 2004; 65: 642-648. (Pubitemid 38130660)
9. Kastritis E, Migkou M, Gavriatopoulou M, Zirogiannis P, Hadjikonstantinou V, Dimopoulos MA. Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica 2009; 94: 300-302.